Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
NCT ID: NCT06599918
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2024-04-23
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is:
\- To determine if the treatment with NAM is able to arrest, or even reduce, the hepatic fibrosis.
In addition, we also want to study the effect of NAM on:
* General parameters (weight, HOMA-IR, etc).
* Adiposity distribution (liver and body).
* Systemic inflammation.
* Thermogenic capacity of adipose tissue.
* Microbiota composition.
Researchers will compare NAM to a placebo, to see if NAM can arrest or revert hepatic fibrosis and its associated effects.
Participants will take either NAM or placebo. The dosage will be 1.2g/m2 NAM per day, for one year.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
NCT03850886
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
NCT01811472
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
NCT02077374
6-week Safety and PD Study in Adults With NAFLD
NCT03256526
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be subjected to a total of 5 follow-up and/or control visits:
Visit 1
* Physical examination(weight, height, BMI, waist circumference, neck circumference, blood pressure, and heart rate).
* Assessment of muscle status and risk of sarcopenia: grip strength, chair test.
* Basal electrocardiogram.
* Blood analysis.
* Bioelectrical impedance analysis.
* Nuclear magnetic resonance.
* Thermographic image.
* Food questionnaire (PREDIMED).
* International Physical Activity Questionnaire (IPAQ).
* Collection of blood, urine, and feces samples for storage in the biobank.
Visit 2. Control visit (time month 1)
* Monitoring of adverse events (AE) and adverse reactions (AR).
* Electrocardiogram.
* Control blood analysis: sodium, potassium, liver biochemistry (AST, ALT, bilirubin, GGT, FA), renal function (urea, creatinine, estimated glomerular filtration), and coagulation tests.
* Physical examination and measurement of vital signs.
Visit 3. Follow-up visit (time month 3)
* Monitoring of AE and AR.
* Drug adherence questionnaire.
* Electrocardiogram.
* Blood analysis.
* Physical examination (weight, BMI, waist circumference, neck circumference, blood pressure, and heart rate).
* Collection of blood, urine, and feces samples for biobank.
* Collection of concomitant medication.
* Adherence to study treatment and dietary recommendations.
Visit 4. Follow-up visit (time month 6)
* Monitoring of AE and AR.
* Drug adherence questionnaire.
* Electrocardiogram.
* Blood analysis.
* Physical examination (weight, BMI, waist circumference, neck circumference, blood pressure, and heart rate).
* Collection of blood, urine, and feces samples for biobank.
* Collection of concomitant medication.
* Adherence to study treatment and dietary recommendations.
Visit 5. Control visit (time month 9).
* Monitoring of AE and AR.
* Drug adherence questionnaire.
* Electrocardiogram.
* Control blood analysis.
* Physical examination.
* Collection of concomitant medication.
Visit 6. Final exploration (time month 12)
* Monitoring of AE and AR.
* Drug adherence questionnaire.
* Food questionnaire (PREDIMED).
* Physical Activity Questionnaire (IPAQ).
* Physical examination and measurement of vital signs (weight, BMI, waist circumference, neck circumference, blood pressure, and heart rate).
* Assessment of muscle status and risk of sarcopenia: FPM, chair test.
* Electrocardiogram.
* Blood analysis.
* Measurement of NAM and derived metabolites in serum and urine.
* Nuclear magnetic resonance.
* Bioimpedance.
* Thermographic image.
* Fibroscan® with CAP.
* Collection of blood, urine, and feces samples for biobank
The safety of the participants will be assessed using a record of the AEs and ARs that could arise and their annotation in the EDC, as well as a regular evaluation of liver, kidney, and heart function at baseline, 1, 3, 6, 9 and 12 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
All personnel from the sponsor and investigator's center involved in the study will undergo masking concerning the assigned treatment, with the following exceptions:
The pharmacy staff at the center involved in the preparation. The Pharmacy Service at Sant Pau Hospital will mask the study medication, labeling it with consecutive code numbers following the randomization table.
The sponsor's pharmacovigilance personnel reporting adverse events to health authorities.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Administration of the placebo compound, in the same format as the active compound.
The placebo is composed by microcrystalline Cellulose (Excipient No. 1 for capsules: 98.05% microcrystalline cellulose, 1.95% colloidal silica). Molecular formula: C14H26O11 IUPAC name: methyl 4-O-methyl-hexopyranosyl-(1-\>4)-hexopyranoside Molecular weight: 370.35 g/mol Qualitative and quantitative composition (per capsule): Microcrystalline Cellulose 400 mg Pharmaceutical form: Hard gelatin capsules containing. Dose and route of administration: maximum 2.4 g daily/oral. Raw material suppliers: Fagron and Acofarma. Encapsulation location: Pharmacy Service of HSCSP.
Placebo
Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Nicotinamide
Administration of the active compound, the amide form of vitamin B3, Nicotinamide (NAM).
International Nonproprietary Name: Nicotinamide. Molecular formula: C6H6N2O IUPAC name: Pyridine-3-carboxamide. Molecular weight: 122.12 g/mol. Qualitative and quantitative composition (per capsule): Nicotinamide 500 mg. Pharmaceutical form: Hard gelatin capsules. Dose and route of administration: maximum 3 g daily/oral. Raw material suppliers: Fagron and Acofarma. Encapsulation location: Pharmacy Service of HSCSP.
Nicotinamide
Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide
Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Placebo
Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of non-alcoholic fatty liver disease (NAFLD) by their referring physicians (NAFLD defined as the presence of hepatic steatosis and in the absence of significant alcohol consumption, having excluded other liver diseases).
* BMI between 27-40 kg/m2.
* Fibroscan® value greater than 9.2 kPa, obtained within the last 6 months prior to the start of the study.
Exclusion Criteria
* History of clinically significant heart disease (ejection fraction \<40% \[normal range 50-70%\], heart failure defined as New York Heart Association \[NYHA\] Class \> 2; clinically significant congenital or acquired valvular disease; symptomatic coronary artery disease such as myocardial infarction or angina, history of unstable arrhythmias, history of atrial fibrillation).
* Decreased renal function (estimated glomerular filtration rate \<45 mL/min/1.73 m2, calculated using the CKD-EPI formula) at screening.
* Alcohol consumption exceeding 30 g/day in men or 20 g/day in women.
* Patients with significant impairment of liver function in the selection analysis defined as repeated values of AST, ALT, and bilirubin \> 3 times the upper limit of normal.
* Positive for hepatitis B surface antigen or hepatitis C antibodies.
* Patients with hepatocellular carcinoma.
* Patients with liver cirrhosis (Fibroscan® \> 18, compatible biopsy, or those who have experienced decompensations of cirrhosis).
* Patients diagnosed with human immunodeficiency virus (HIV).
* Patients with hypersensitivity or a history of severe allergies to NAM or excipients used in the preparation of capsules (NAM and placebo).
* Patients with iodinated contrast allergy.
* History or evidence of an autoimmune disorder considered clinically significant by the investigator or requiring systemic, chronic use of systemic corticosteroids or other immunosuppressants.
* Patients on treatment with hepatotoxic drugs (amiodarone, immunosuppressants, ART, antituberculosis drugs, corticosteroids, etc.).
* Patients consuming narcotic and psychotropic substances with hepatotoxic effects.
* Individuals with incapacitating diseases or cognitive impairment.
* Institutionalized patients or those without a fixed address.
* Principal investigator's discretion in case of indications of low adherence to the trial or follow-up visits.
* Individuals with a life expectancy of less than 12 months.
* Patients participating in another interventional clinical trial, excluding observational/natural history studies, at the start of the study or within the last 30 days before the start of the study.
* Previous use of vitamin B3 (NAM), with abstinence required for at least 3 months before screening.
* Pregnant women as determined by a positive high-sensitivity serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent units of hCG) within 24 hours prior to screening, dosing, or completion of the study. Women of childbearing potential (WOCBP) will undergo a pregnancy test (serum or urine) 24 hours prior to screening, dosing, or completion of the study. Such participants must use a highly effective contraceptive method, such as combined hormonal contraceptives or intrauterine device (IUD), in accordance with the Clinical Trial Facilitation Group, throughout the entire study.
* Breastfeeding women.
* Patients undergoing treatment/supplementation with vitamin E.
* Patients receiving probiotics.
* Patients on the waiting list for bariatric surgery in the next 12 months.
* Patients undergoing treatment with drugs that may have an effect on the progression of liver disease.
* Drugs for the treatment of T2DM with effects on NAFLD (GLP-1 analogs, thiazolidinediones such as pioglitazone) initiated within 6 months before the study start.
* Drugs for the treatment of T2DM with effects on intestinal microbiota (metformin, α-GI inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) initiated within 6 months before the study start.
* Patients who do not sign the informed consent.
* Patients with contraindications to the contrast agent to be used in imaging tests.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Germans Trias i Pujol Hospital
OTHER
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504100-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
IIBSP-NIC-2021-157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.